15 companies

Inventiva

Market Cap: €806.9m

A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.

IVA

€3.42

7D

12.9%

1Y

29.1%

Valneva

Market Cap: €438.1m

A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.

VLA

€2.31

7D

4.3%

1Y

-3.3%

Cellectis

Market Cap: €204.9m

A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.

ALCLS

€2.82

7D

13.5%

1Y

106.6%

Innate Pharma

Market Cap: €160.4m

Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.

IPH

€1.71

7D

6.6%

1Y

11.8%

Sensorion

Market Cap: €132.8m

A biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.

ALSEN

€0.26

7D

11.2%

1Y

-25.9%

OSE Immunotherapeutics

Market Cap: €84.2m

A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.

OSE

€3.58

7D

15.5%

1Y

-27.7%

Adocia

Market Cap: €82.8m

A clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity.

ADOC

€4.23

7D

4.1%

1Y

15.3%

ABIONYX Pharma

Market Cap: €72.0m

A biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States.

ABNX

€2.04

7D

-0.5%

1Y

70.0%

AB Science

Market Cap: €60.8m

A clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France.

AB

€0.76

7D

-15.4%

1Y

-50.8%

MaaT Pharma

Market Cap: €51.6m

A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.

MAAT

€2.74

7D

11.8%

1Y

-45.8%

THX Pharma Société Anonyme

Market Cap: €50.2m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€3.64

7D

8.7%

1Y

184.4%

Nicox

Market Cap: €34.7m

Operates as an ophthalmology company in France and internationally.

ALCOX

€0.39

7D

5.3%

1Y

76.3%

Advicenne

Market Cap: €32.2m

A specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally.

ALDVI

€2.21

7D

66.2%

1Y

63.9%

GenSight Biologics

Market Cap: €19.5m

A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.

SIGHT

€0.083

7D

3.7%

1Y

-37.1%

Valbiotis

Market Cap: €19.4m

Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France and Asia.

ALVAL

€0.82

7D

2.5%

1Y

-0.6%